After first reviewing the pathways and interactions associated with the activation of normal T-cells by Interleukin (IL), A. Krajewski (Edinburgh) went on to describe a study of leukaemic T-cells in terms of production of and response to IL. There is currently some doubt that the producers of human IL-2 invariably belong to the helper/inducer (OKT4+) subsets of T-cells. However, in the study reported, all three OKT4+ T-cell -chronic lymphocytic leukaemias (T-CLL) produced IL-2 when stimulated with phytohaemagglutinin (PHA) . In each case the mobility of the active molecule on Sephadex G-100 paralleled that described for IL-2 by other authors. A single T-CLL of suppressor/cytotoxic phenotype (OKT8+) did not produce the growth factor following mitogenic stimulation. All cases of OKT4+ and T-CLL gave a good proliferative response in soft agar. When stimulated with mitogen and IL-1 or IL-2, the OKT8+ tumour responded only to IL-2 and PHA. In each case the phenotype of the cells obtained from colonies in agar corresponded to that of the original neoplastic population. Proliferative responses are not produced with highly purified IL-2 alone, suggesting that growth factor and an activation signal are required to induce proliferation in T-CLL. The data suggest that in the growth system studied T-cell leukaemia obeys the rules described for normal T-cells.
Kaposi's Sarcoma (KS) has a high incidence in many parts of tropical Africa. Considerable interest has recently been prompted in the West by the appearance of thiis tumour in individuals with the Aquired Immunodeficiency Syndrome (AIDS) and its relationship to Human T-cell leukaemia virus (HTLV). R. Downing (Porton Down) has investigated the incidence of antibodies to HTLV in Zambian patients with KS and their associates. It is often argued that tumours of the B-cell series arise by transformation of progenitor cells. This is clearly the case for common acute lymphoblastic leukaemia and the lymphoblastic form of chronic myeloid leukaemia. The evidence that chronic lymphocyte leukaemia (CLL) arises from an early B-cell within the bone marrow is less persuasive. In their presentation on the clonogenic cell in B-lymphocyte neoplasia L MacLennan and N. Ling (Birmingham) described the events which occur during lymphogenesis in adult bone marrow and showed that phenotypically CLL does not resemble any cell within this developmental series. A Supernatants of the L428 cell line have been shown to exhibit lymphokine-like activity an observation relevant to the development of the reactive stroma in HD. The Southampton cell line, which resembles L428 and carries the Ki-l antigen, has also been shown to exhibit an isoenzyme pattern for non-specific esterase which is uncharacteristic of any other cell type examined, (D.B. Jones, Southampton and S. Scott, Leeds). This result further suggests that RS and HC cells represent a unique cell lineage.
P. Beverley (London) provided cautionary data on the use of monoclonal antibodies in defining T-cells which complemented earlier comments on cells of the macrophage lineage. It is clear from studies of normal cell populations that phenotype may vary both through development and after neoplastic transformation. The physiological environment in which a cell exists may also affect phenotype. A cloned T-cell line responsive to P20, an antigen derived from influenza virus haemagglutinin, shows increased levels of an activation marker after binding of P20. Data on marrow involvement were also presented by J. Smith (Southampton) who described the results of a study of blood and marrow involvement in Non-Hodgkin's Lymphoma (NHL) patients in the Medical Oncology Trial Group. A total of 184 NHL patients have been assessed by the Lymphoma Study Group and phenotypic analysis of blood and marrow is available for 107 of these. It is clear that immunological methods greatly improve the sensitivity of diagnosis of marrow involvement when compared with either cytological analysis of marrow aspirates (53% positive in comparison with 18%) or with the histological examination of trephine biopsies (33%). Monoclonal B-cell populations can also be readily identified in the blood in NHL of low and highgrade malignancy. The analysis of survival data for patients with high grade malignancy shows that the immunological investigation of the bone marrow provides information of value in staging and for prognostic purposes. In 
